Blue Water Life Science Advisors, LP
In its 13F for Q4 2024 (holdings as of December 31, 2024, filed February 13, 2025), Blue Water Life Science Advisors, LP reported 9 stock positions worth $112.9 million. Its top holding was Natera (NTRA) at 35.7% of the portfolio, followed by Guardant Health (GH, 18.8%) and Caredx (CDNA, 11.5%). Compared with Q3 2024, it opened 1 new position, added to 2 and reduced 2. The biggest buy was Guardant Health (GH, shares +54%) and the biggest sale Exact Sciences (EXAS, shares −69%).
- Most Recent 13F
- Q2 2026
- Location
- LARKSPUR, CA
- CIK
- 0001789778
- Portfolio Value
- $112.9M (Q4 2024)
- SEC Filing
- 0001420506-25-000379 ↗ filed Feb 13, 2025
Holdings Value
Holdings 9 stocks · $112.9M
| NTRA Natera Inc. | 35.71% | 254,794 | $40.3M | Reduce -12.5% |
| GH Guardant Health Inc. | 18.77% | 694,047 | $21.2M | Add +53.9% |
| CDNA Caredx Inc. | 11.45% | 604,000 | $12.9M | No change |
| ADPT Adaptive Biotechnologies | 11.39% | 2,145,145 | $12.9M | No change |
| AKYA Akoya Biosciences Inc. | 9.53% | 4,697,785 | $10.8M | No change |
| PSNL Personalis Inc. | 5.80% | 1,132,900 | $6.5M | Add +13.3% |
| EXAS Exact Sciences Corp. | 3.92% | 78,843 | $4.4M | Reduce -69.1% |
| TEM Tempus AI Inc. Class A | 2.69% | 90,000 | $3.0M | New |
| QTRX Quanterix Corp. | 0.74% | 78,393 | $833K | No change |
Portfolio Sells Q3 2024 → Q4 2024
Portfolio Buys Q3 2024 → Q4 2024
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 9 | $158.8M | CDNA, TXG, PSNL, ADPT, GH |
| Q1 2026 | 10 | $124.7M | TXG, GH, CDNA, ADPT, TWST |
| Q4 2025 | 9 | $159.3M | GH, NTRA, ADPT, PSNL, QTRX |
| Q3 2025 | 7 | $109.6M | ADPT, GH, NTRA, PSNL, CDNA |
| Q2 2025 | 8 | $126.3M | NTRA, ADPT, GH, CDNA, TXG |
| Q1 2025 | 7 | $100.9M | GH, NTRA, ADPT, CDNA, AKYA |
| Q4 2024 | 9 | $112.9M | NTRA, GH, CDNA, ADPT, AKYA |
| Q3 2024 | 8 | $113.7M | NTRA, CDNA, EXAS, AKYA, ADPT |
| Q2 2024 | 8 | $102.8M | NTRA, GH, AKYA, CDNA, TXG |
| Q1 2024 | 8 | $106.3M | NTRA, AKYA, GH, TXG, QTRX |